cystic fibrosis transmembrane conductance regulator (505-511) has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 1 studies
| Studies (cystic fibrosis transmembrane conductance regulator (505-511)) | Trials (cystic fibrosis transmembrane conductance regulator (505-511)) | Recent Studies (post-2010) (cystic fibrosis transmembrane conductance regulator (505-511)) | Studies (1,3-dipropyl-8-cyclopentylxanthine) | Trials (1,3-dipropyl-8-cyclopentylxanthine) | Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine) |
|---|---|---|---|---|---|
| 17 | 1 | 3 | 1,301 | 1 | 165 |
| Protein | Taxonomy | cystic fibrosis transmembrane conductance regulator (505-511) (IC50) | 1,3-dipropyl-8-cyclopentylxanthine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0051 | |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | 0.0038 | |
| Adenosine receptor A2a | Homo sapiens (human) | 0.2033 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.0234 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR | 1 |
1 trial(s) available for cystic fibrosis transmembrane conductance regulator (505-511) and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose-Response Relationship, Drug; Female; Humans; Male; Membrane Potentials; Mutation, Missense; Nasal Mucosa; Peptide Fragments; Purinergic P1 Receptor Antagonists; Regression Analysis; Research Design; Sweat; Treatment Outcome; Xanthines | 2002 |